342 related articles for article (PubMed ID: 33511267)
1. Immune response in glioma's microenvironment.
Chen H; Li M; Guo Y; Zhong Y; He Z; Xu Y; Zou J
Innov Surg Sci; 2020 Dec; 5(3-4):20190001. PubMed ID: 33511267
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells in gliomas.
Gieryng A; Kaminska B
Contemp Oncol (Pozn); 2016; 20(5):345-351. PubMed ID: 28373814
[TBL] [Abstract][Full Text] [Related]
4. Insights in the immunobiology of glioblastoma.
Strepkos D; Markouli M; Klonou A; Piperi C; Papavassiliou AG
J Mol Med (Berl); 2020 Jan; 98(1):1-10. PubMed ID: 31650201
[TBL] [Abstract][Full Text] [Related]
5. Deciphering immune microenvironment and cell evasion mechanisms in human gliomas.
Rafii S; Kandoussi S; Ghouzlani A; Naji O; Reddy KP; Ullah Sadiqi R; Badou A
Front Oncol; 2023; 13():1135430. PubMed ID: 37274252
[TBL] [Abstract][Full Text] [Related]
6. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
7. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
8. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.
Won WJ; Deshane JS; Leavenworth JW; Oliva CR; Griguer CE
Cell Stress; 2019 Jan; 3(2):47-65. PubMed ID: 31225500
[TBL] [Abstract][Full Text] [Related]
10. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models.
Alghamri MS; Kamran N; Kadiyala P; Lowenstein PR; Castro MG
Methods Enzymol; 2020; 632():215-228. PubMed ID: 32000897
[TBL] [Abstract][Full Text] [Related]
11. The Role of Myeloid Cells in GBM Immunosuppression.
Lin YJ; Wu CY; Wu JY; Lim M
Front Immunol; 2022; 13():887781. PubMed ID: 35711434
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell Omics in Dissecting Immune Microenvironment of Malignant Gliomas-Challenges and Perspectives.
Kaminska B; Ochocka N; Segit P
Cells; 2021 Aug; 10(9):. PubMed ID: 34571910
[TBL] [Abstract][Full Text] [Related]
13. The Pivotal Immunoregulatory Functions of Microglia and Macrophages in Glioma Pathogenesis and Therapy.
Richard SA
J Oncol; 2022; 2022():8903482. PubMed ID: 35419058
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth.
Wang J; Leavenworth JW; Hjelmeland AB; Smith R; Patel N; Borg B; Si Y; King PH
Glia; 2019 Dec; 67(12):2424-2439. PubMed ID: 31400163
[TBL] [Abstract][Full Text] [Related]
16. [The immunosuppressive microenvironment of malignant gliomas].
Borisov KE; Sakaeva DD
Arkh Patol; 2015; 77(6):54-63. PubMed ID: 26841651
[TBL] [Abstract][Full Text] [Related]
17. Siglec10-An immunosuppressor and negative predictor of survival prognosis in gliomas.
Wang H; Feng Y; Zhang Y; Wang T; Xu H; Zhi Y; Feng Y; Tian L; Yuan K
Front Genet; 2022; 13():873655. PubMed ID: 36468012
[TBL] [Abstract][Full Text] [Related]
18. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
19. Origin, activation, and targeted therapy of glioma-associated macrophages.
Xu C; Xiao M; Li X; Xin L; Song J; Zhan Q; Wang C; Zhang Q; Yuan X; Tan Y; Fang C
Front Immunol; 2022; 13():974996. PubMed ID: 36275720
[TBL] [Abstract][Full Text] [Related]
20. Tumor infiltrating immune cells in gliomas and meningiomas.
Domingues P; González-Tablas M; Otero Á; Pascual D; Miranda D; Ruiz L; Sousa P; Ciudad J; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
Brain Behav Immun; 2016 Mar; 53():1-15. PubMed ID: 26216710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
